Impact of Empagliflozin on Blood Pressure in Patients with Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication

Hypertension

Volumn 68, Issue 6, 2016, Pages 1355-1364

  Mancia, Giuseppe ^a   Cannon, Christopher P ^b   Tikkanen, Ilkka ^c   Zeller, Cordula ^d   Ley, Ludwin ^d   Woerle, Hans J ^d   Broedl, Uli C ^d   Johansen, Odd Erik ^e  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e Boehringer Ingelheim Norway KS   (Norway)

Author keywords

antihypertensive; blood pressure; diuretic; empagliflozin; hypertension; SGLT2 inhibitor; type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EMPAGLIFLOZIN; PLACEBO; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; GLUCOSE BLOOD LEVEL; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; REFERENCE VALUE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE DETERMINATION; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLUCOSIDES; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; PROSPECTIVE STUDIES; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84994853573     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07703     Document Type: Article

References (28)

1. Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2014;7:169-183. doi: 10.2147/DMSO.S61438.
2. Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013;6:327-338. doi: 10.2147/DMSO.S51325.
3. de Galan BE, Perkovic V, Ninomiya T, et al.; ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883-892. doi: 10.1681/ASN.2008070667.
4. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219. doi: 10.1093/eurheartj/eht151.
5. Handelsman Y, Mechanick JI, Blonde L, et al.; AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(suppl 2):1-53.
6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379. doi: 10.2337/dc12-0413.
7. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care. 2014;37(suppl 1):S14-S80. doi: 10.2337/dc14-S014.
8. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. doi: 10.1001/jama.2013.284427.
9. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013;36:2271-2279. doi: 10.2337/dc12-2258.
10. Nelson SA, Dresser GK, Vandervoort MK, Wong CJ, Feagan BG, Mahon JL, Feldman RD. Barriers to blood pressure control: a STITCH substudy. J Clin Hypertens (Greenwich). 2011;13:73-80. doi: 10.1111/j.1751-7176.2010.00392.x.
11. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002;20:1461-1464.
12. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727-1736. doi: 10.1161/CIRCULATIONAHA.110.008870.
13. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:613-621. doi: 10.1111/dom.12073.
14. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369-384. doi: 10.1016/S2213-8587(13)70208-0.
15. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG METSU Trial Investigators. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36:3396-3404. doi: 10.2337/dc12-2673.
16. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650-1659. doi: 10.2337/dc13-2105.
17. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG PIO™ trial investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147-158. doi: 10.1111/dom.12188.
18. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC; EMPA-REG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208-219. doi: 10.1016/S2213-8587(13)70084-6.
19. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.
20. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ; EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420-428. doi: 10.2337/dc14-1096.
21. Weber MA, Mansfield TA, Alessi F, Iqbal N, Parikh S, Ptaszynska A. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press. 2016;25:93-103. doi: 10.3109/08037051.2015.1116258.
22. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28. doi: 10.1186/1475-2840-13-28.
23. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180-1193. doi: 10.1111/dom.12572.
24. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res. 2015;116:1034-1045. doi: 10.1161/CIRCRESAHA.116.303755.
25. Cherney D, Cooper M, Tikkanen I, Crowe S, Johansen OE, Lund SS, Woerle HJ4, Broedl UC, Hach T. Contrasting influences of renal function on blood pressure and HbA1c reductions with empagliflozin in patients with type 2 diabetes and hypertension. Circulation. 2014;130:A16709.
26. Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens. 2015;9:48-53. doi: 10.1016/j. jash.2014.11.001.
27. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90-100. doi: 10.1177/1479164114559852.
28. Tikkanen I, Chilton R, Johansen OE. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. Curr Opin Nephrol Hypertens. 2016;25:81-86. doi: 10.1097/MNH.0000000000000199.